

Claims

1. A compound of formula **I** or **I′**



I



I′;

or a pharmaceutically acceptable salt thereof,

wherein, independently for each occurrence:

Y is C or N

R^1 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^2 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^3 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^4 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^5 is H, halogen, CN, or $–X-R^X$;

$R^{5'}$ is H, halogen, CN, or $–X-R^X$;

R^6 is H, halogen, CN, or $–X-R^X$;

$R^{6'}$ is H, halogen, CN, or $–X-R^X$;

R^7 is H, halogen, CN, or $–X-R^X$;

X is a bond or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^X is absent, H, or C_3-C_8 cycloaliphatic, wherein up to two non-adjacent CH_2 units of said C_3-C_8 cycloaliphatic may be replaced with -O- and said C_3-C_8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C_1-C_4 alkyl;

R^8 is halogen, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

p is an integer from 0 to 4 inclusive; and

provided the following compounds are excluded:

4-methyl-3-(2-phenoxybenzamido)benzoic acid;

3-(2-phenoxybenzamido)benzoic acid;


4-chloro-3-(2-phenoxybenzamido)benzoic acid;

3-methyl-4-[(2-phenoxybenzoyl)amino]-benzoic acid;

4-[(2-phenoxybenzoyl)amino]-benzoic acid; and

5-chloro-2-methoxy-4-[(2-phenoxybenzoyl)amino]-benzoic acid.

2. A compound of formula **I**



I

or a pharmaceutically acceptable salt thereof,

wherein, independently for each occurrence:

Y is C or N

R^1 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^2 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^3 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^4 is H, halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^5 is H, halogen, CN, or –X-R^X;

$R^{5'}$ is H, halogen, CN, or –X-R^X;

R^6 is H, halogen, CN, or –X-R^X;

$R^{6'}$ is H, halogen, CN, or –X-R^X;

R^7 is H, halogen, CN, or –X-R^X;

X is a bond or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^X is absent, H, or C_3-C_8 cycloaliphatic, wherein up to two non-adjacent CH_2 units of said C_3-C_8 cycloaliphatic may be replaced with -O- and said C_3-C_8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C_1-C_4 alkyl;

R^8 is halogen, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

p is an integer from 0 to 4 inclusive; and

provided the following compounds are excluded:

3-methyl-4-[(2-phenoxybenzoyl)amino]-benzoic acid;

4-[(2-phenoxybenzoyl)amino]-benzoic acid; and

5-chloro-2-methoxy-4-[(2-phenoxybenzoyl)amino]-benzoic acid.

3. The compound or pharmaceutically acceptable salt according to claim 1 or 2, wherein R^1 is H or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen.

4. The compound or pharmaceutically acceptable salt according to claim 3, wherein R^1 is CF_3.

5. The compound or pharmaceutically acceptable salt according to claim 1 or 2, wherein R^2 is H, halogen, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen and wherein one CH_2 unit of said C_1-C_6 alkyl is replaced with -O.

6. The compound or pharmaceutically acceptable salt according to claim 5, wherein R^2 is F, Cl, CF_3 or OCF_3.


7. The compound or pharmaceutically acceptable salt according to claim 1 or 2, wherein R^3 is halogen or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen.

8. The compound or pharmaceutically acceptable salt according to claim 7, wherein R^3 is *t*-butyl, Cl, CF_3 or CF_2CF_3.


9. The compound or pharmaceutically acceptable salt according to any one of claims 1, 2, 7 or 8, wherein R^5 and R^7 are each independently halogen, or –X-R^X and $R^{5'}$, R^6, and $R^{6'}$ are each hydrogen.

10. The compound or pharmaceutically acceptable salt according to claim 9, wherein R^5 and R^7 are each independently F, Cl, CH_3 or OCH_3.

11. The compound or pharmaceutically acceptable salt according to claim 1 or 2, wherein ring A is:



12. The compound or pharmaceutically acceptable salt according to claim 11, wherein ring A is:




13. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 12, wherein p is 0.

14. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 13, wherein Y is N.

15. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 13, wherein Y is C.

16. The compound of claim 1, wherein the compound has formula **I-B** or **I′-B**:



I-B **I′-B**

or a pharmaceutically acceptable salt thereof,

wherein, independently for each occurrence:

Y is C or N;

R^3 is halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^5 is H, halogen, CN, or –X-R^X;

$R^{5'}$ is H, halogen, CN, or –X-R^X;

R^6 is H, halogen, CN, or –X-R^X;

$R^{6'}$ is H, halogen, CN, or –X-R^X;

R^7 is H, halogen, CN, or –X-R^X;

X is a bond or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^X is absent, H, or C_3-C_8 cycloaliphatic, wherein up to two non-adjacent CH_2 units of said C_3-C_8 cycloaliphatic may be replaced with -O- and said C_3-C_8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C_1-C_4 alkyl;

R^8 is halogen, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-; and


p is an integer from 0 to 4 inclusive.

17. The compound or pharmaceutically acceptable salt according to claim 16, wherein R^3 is C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen.

18. The compound or pharmaceutically acceptable salt according to claim 16 or 17, wherein R^3 is *t*-butyl, Cl, CF_3 or CF_2CF_3.


19. The compound or pharmaceutically acceptable salt according to any one of claims 16 to 18, wherein R^5 and R^7 are each independently F, Cl, CH_3 or OCH_3.

20. The compound or pharmaceutically acceptable salt according to claim 16, wherein ring A is:




21. The compound or pharmaceutically acceptable salt according to any one of claims 16 to 20, wherein p is 0.

22. The compound according to claim 1, wherein the compound has formula **I-C** or **I′-C**:



I-C



I′-C

or a pharmaceutically acceptable salt thereof,

wherein, independently for each occurrence:

Y is C or N;

R^2 is halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^3 is halogen, CN, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^5 is H, halogen, CN, or –X-R^X;

$R^{5'}$ is H, halogen, CN, or –X-R^X;

R^6 is H, halogen, CN, or –X-R^X;

$R^{6'}$ is H, halogen, CN, or –X-R^X;

R^7 is H, halogen, CN, or –X-R^X;

X is a bond or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-;

R^X is absent, H, or C_3-C_8 cycloaliphatic, wherein up to two non-adjacent CH_2 units of said C_3-C_8 cycloaliphatic may be replaced with -O- and said C_3-C_8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C_1-C_4 alkyl;

R^8 is halogen, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH_2 units of said C_1-C_6 alkyl may be replaced with -O-; and

p is an integer from 0 to 4 inclusive.

23. The compound or pharmaceutically acceptable salt according to claim 22, wherein R^2 is H, halogen, or C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen and wherein one CH_2 unit of said C_1-C_6 alkyl is replaced with -O-.


24. The compound or pharmaceutically acceptable salt according to claim 23, wherein R^2 is F, Cl, CF_3 or OCF_3.

25. The compound or pharmaceutically acceptable salt according to any one of claims 22 to 24, wherein R^3 is C_1-C_6 alkyl wherein said C_1-C_6 alkyl is substituted with 0-6 halogen.

26. The compound or pharmaceutically acceptable salt according to claim 25, wherein R^3 is *t*-butyl, Cl, CF_3 or CF_2CF_3.

27. The compound or pharmaceutically acceptable salt according to any one of claims 22 to 26, wherein R^5 and R^7 are each independently F, Cl, CH_3 or OCH_3.


28. The compound or pharmaceutically acceptable salt according to claim 22, wherein ring A is:




or

29. The compound or pharmaceutically acceptable salt according to any one of claims 22 to 28, wherein p is 0.


30. The compound or pharmaceutically acceptable salt of claim 1, wherein the compound or pharmaceutically acceptable salt is selected from the group consisting of:




4-(2-(2-chloro-4-fluorophenoxy)-4-(perfluoroethyl)benzamido)benzoic acid;




4-(2-(2,4-difluorophenoxy)-4-(perfluoroethyl)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methylphenoxy)-4-(perfluoroethyl)benzamido)benzoic acid;




4-(2-(2-chloro-4-fluorophenoxy)-4-(trifluoromethyl)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methylphenoxy)-4-(trifluoromethyl)benzamido)benzoic acid;




4-(2-(2,4-difluorophenoxy)-4-(trifluoromethyl)benzamido)benzoic acid;




4-(2-(4-(trifluoromethoxy)phenoxy)-4-(trifluoromethyl)benzamido)benzoic acid;




4-(2-(2,4-difluorophenoxy)-4,6-bis(trifluoromethyl)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methylphenoxy)-4,6-bis(trifluoromethyl)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)benzoic acid;




4-(2-(4-fluorophenoxy)-4,6-bis(trifluoromethyl)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-fluorophenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-fluoro-2-methylphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-phenoxybenzamido)benzoic acid;




4-(4,5-dichloro-2-(2-fluoro-4-methoxyphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-(2,2,2-trifluoroethoxy)phenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-chloro-2-methoxyphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(2-(difluoromethoxy)phenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-chloro-2-methylphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(2,4-dimethoxyphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(2-chloro-4-fluorophenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(2,4-difluorophenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(2-chloro-4-methoxyphenoxy)benzamido)benzoic acid;




4-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoic acid;




4-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)benzoic acid;




5-(4,5-dichloro-2-(4-fluorophenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-(isopentyloxy)phenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-fluoro-2-methylphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-phenoxybenzamido)picolinic acid;




5-(4,5-dichloro-2-(2-fluoro-4-methoxyphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-(2,2,2-trifluoroethoxy)phenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-chloro-2-methoxyphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(2-(difluoromethoxy)phenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-chloro-2-methylphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(2,4-dimethoxyphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(3-fluoro-4-methoxyphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(2-chloro-4-fluorophenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(2,4-difluorophenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(2-chloro-4-methoxyphenoxy)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)picolinic acid;




5-(2-(2-methoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-methoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-fluoro-2-methylphenoxy)-4,6-bis(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-fluoro-2-methoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2,4-dimethoxyphenoxy)-4,6-bis(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-fluorophenoxy)-4,6-bis(trifluoromethyl)benzamido)picolinic acid;




5-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)picolinic acid;




5-(4-(tert-butyl)-2-(4-fluoro-2-methoxyphenoxy)benzamido)picolinic acid;




5-(4-(tert-butyl)-2-(4-fluoro-2-methylphenoxy)benzamido)picolinic acid;




5-(4-(tert-butyl)-2-(4-fluorophenoxy)benzamido)picolinic acid;




5-(2-(4-fluorophenoxy)benzamido)picolinic acid;




5-(2-(4-fluorophenoxy)-4-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-fluoro-2-methoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2-chloro-4-fluorophenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(5-fluoro-2-methoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2-(difluoromethoxy)phenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-chloro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2-methoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2-chlorophenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2-isopropoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2,4-dimethoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-chloro-2-methoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-methoxy-2-methylphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(2-chloro-4-methoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(3-fluoro-2-methoxyphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-phenoxy-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-fluorophenoxy)-5-(trifluoromethyl)benzamido)picolinic acid;




5-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamido)picolinic acid;




5-(2-(4-fluorophenoxy)-4-(perfluoroethyl)benzamido)picolinic acid;



5-(2-(2-chloro-4-fluorophenoxy)-6-(trifluoromethyl)benzamido)picolinic acid;



5-(2-(4-fluoro-2-methylphenoxy)-5-(trifluoromethyl)benzamido)picolinic acid; and



5-(4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)benzamido)picolinic acid;

or a pharmaceutically acceptable salt thereof.

31. A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 30 and one or more pharmaceutically acceptable carriers or vehicles.

32. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 30 and one or more pharmaceutically acceptable carriers or vehicles.

33. A compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 30 or a pharmaceutical composition according to claim 31 or 32 for use in a method of inhibiting a voltage-gated sodium channel in a subject.

34. A compound or a pharmaceutically acceptable salt or a pharmaceutical composition for the use according to claim 33, wherein the voltage-gated sodium channel is Nav1.8.

35. A compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 30 or a pharmaceutical composition of claim 31 or 32 for use in a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia.

36. Use of a compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 30 or a pharmaceutical composition of claim 31 or 32 in the manufacture of a medicament for treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia.

37. The use according to claim 36, wherein the medicament is for treating or lessening the severity in a subject of gut pain, wherein gut pain comprises inflammatory bowel disease pain, Crohn’s disease pain or interstitial cystitis pain.

38. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of neuropathic pain, wherein neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma; traumatic neuroma; Morton’s neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia; post spinal cord injury pain, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia.

39. The use according to claim 38, wherein neuropathic pain comprises idiopathic small-fiber neuropathy.

40. The use according to claim 38, wherein neuropathic pain comprises post-herpetic neuralgia.

41. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of musculoskeletal pain, wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, burn pain or dental pain.

42. The use according to claim 41, wherein musculoskeletal pain comprises osteoarthritis pain.

43. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain or vulvodynia.

44. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of idiopathic pain, wherein idiopathic pain comprises fibromyalgia pain.

45. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of acute pain.

46. The use according to claim 45, wherein acute pain comprises acute post-operative pain.

47. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of postsurgical pain.

48. The use according to claim 36, wherein the medicament is for treating or lessening the severity in the subject of visceral pain.

49. The use according to any one of claims 36 to 48, wherein the subject is to be treated with one or more additional therapeutic agents to be administered concurrently with, prior to, or subsequent to treatment with the compound, pharmaceutically acceptable salt thereof, or pharmaceutical composition.